iDEL Therapeutics
Developing a pipeline of cancer therapeutics delivered directly into the cytosol of tumor cells.
About
iDEL Therapeutics is a Dortmund-based startup focused on developing novel cancer therapeutics. Their core technology is a synthetic shuttle platform designed to deliver drugs directly into the cytosol of tumor cells, evading endosomal trapping and preventing degradation. This platform is compatible with both large and small molecules, including nanobodies and cytotoxic payloads, aiming to unlock historically undruggable intracellular targets and broaden therapeutic windows. Teams look it up for Biotechnology, Pharmaceuticals, Oncology.
Frequently asked
What does iDEL Therapeutics do?
iDEL Therapeutics is a Biotechnology company that offers Platform. Teams look it up for Pharmaceuticals, Oncology, Drug Delivery. It is based in Dortmund, Germany and was founded in 2025. Public records show $10M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has iDEL Therapeutics raised?
iDEL Therapeutics has raised a total of $10M in funding. The most recent round on record is Seed.
Where is iDEL Therapeutics headquartered?
iDEL Therapeutics is headquartered in Dortmund, Germany.
When was iDEL Therapeutics founded?
iDEL Therapeutics was founded in 2025.
What industry does iDEL Therapeutics operate in?
iDEL Therapeutics operates in Biotechnology, Pharmaceuticals, Oncology, Drug Delivery.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.